Some diseases are so rare that the drug industry mostly ignores them. KCNT1+ epilepsy is one of them, and it just got a lot harder to ignore.
Jazz Pharmaceuticals announced Monday that it is buying Actio Biosciences for $820 million upfront.
There is another $500 million on the table if ABS-1230 hits certain approval or sales milestones.
The drug is a pill designed for KCNT1+ epilepsy, a rare genetic form of the condition. Right now, no FDA-approved treatment exists for it, which is exactly the gap Jazz is paying to fill.
The condition is ultra-rare, which is part of why no one has developed a treatment for it.
Early clinical trial results for ABS-1230 have been encouraging, but the drug still has a long road ahead.
For a disease with no treatment at all, though, the promise alone is enough to get a deal done. That is the bet behind the $820 million.
This is not Jazz's first move in rare epilepsy.
The company already sells drugs for rare cancers and sleep disorders, and it has been building out a lineup of treatments for rare forms of epilepsy.
Get the free Always Be Buying eBook and learn the simple system for building wealth on any income
ABS-1230 would join that family. It has also made it into an FDA program that supports therapies for ultra-rare diseases.
That program gives therapies for ultra-rare diseases extra help as they move through the approval process.
For a drug with no approved rivals, that is a meaningful step.
The structure of the deal is common in biotech: the upfront payment buys the science, and the milestone payments only kick in if the drug actually reaches its goals.
That means Jazz does not pay the full price unless the drug delivers.
There is another piece to the deal. Actio will spin off its non-epilepsy projects into a new private company focused on rare inherited neurological conditions.
Jazz retains a small ownership share in that new entity, so it stays connected to the work without owning it.
That keeps the other projects moving while Jazz focuses on the epilepsy drug.
Both companies' boards have approved the deal, and the two sides expect to close in Q4 of this year. That gives Jazz and Actio a few months to work through the details.
Closing the deal is just the beginning for ABS-1230.
The drug still has to prove itself in more trials and win approval before it can reach patients, and many drugs never make it that far.
Renee Gala, Jazz's president and CEO, said in a statement: "The emerging clinical profile of ABS-1230 is highly encouraging, and we look forward to closing the proposed transaction and collaborating with our new Actio Biosciences colleagues to address an urgent patient need."
Drug development is a long game, and early promise does not guarantee a finish line. Every biotech deal carries that risk, including this one.
For investors, this is a bet on a drug that could become the first approved treatment for a disease that has none.
For the families living with KCNT1+ epilepsy, the numbers are not the point. They are hoping this pill becomes the first treatment they have ever had.
That hope is what the $820 million is really buying.
Download the free Always Be Buying eBook and start putting your money to work today
